Abstract P1-18-10: A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)
Sacha J. Howell(The Christie NHS Foundation Trust), R. Charles Coombes(Imperial College London), Anthony GM Barrett(Imperial College London), Matthew J. Fuchter(University of Oxford), Stuart McIntosh(Queen's University Belfast), Iain R. Macpherson(Beatson West of Scotland Cancer Centre), Laura Kenny(Charing Cross Hospital), Edward Ainscow, Simak Ali(The London College), Glen Clack(University of Sheffield), M. Lehnert(Merck & Co., Inc., Rahway, NJ, USA (United States)), Richard D. Baird(Cancer Research UK), Matthew Krebs(Christie's), Simon Lord(University of Oxford), Hendrik‐Tobias Arkenau(Sarah Cannon Research Institute), Ash Bahl(Loughborough University), Paul A. Dickinson
Cited by 5
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2015|799